Sales Rise In 1995 At Egis

30 June 1996

Egis of Hungary saw net sales in 1995 rise to 19.8 billion forint ($129.9 million), of which 8.9 billion forint came from exports, 29.5% higher than in 1994, reports MTI Econews. Exports in 1995 were 2.1 billion forint higher than in the previous year. 80.3% of the firm's sales come from human pharmaceuticals, 17.7% from active ingredients, 0.5% from veterinary medicines, and 1.2% from baby formulas.

Operating profits for the year were just over 4 billion forint, up 33.8%. Gross profits were 4.9 billion forint, 92.7% higher than in the previous year.

In the current year, Egis plans to increase its revenues by 28%, with a higher rate of increase in exports. Its 1996 business plan envisages a 29% increase in operating profits, mainly resulting from a better product structure and planned savings in operational costs. Egis plans to invest 2.8 billion forint this year, and spend 500 million forint on developing operations.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight